Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
- 6 May 1994
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 264 (5160), 833-835
- https://doi.org/10.1126/science.8171337
Abstract
Tumor immunotherapy should increase both the number of T cells that kill the tumor and the likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies (Bi-mAbs) were designed that bound to a Hodgkin's tumor-associated antigen (CD30) on the tumor and to either CD3 or CD28 on the T cell. Immunodeficient mice were cured of established human tumors when mice were treated with both the CD3-CD30 and the CD28-CD30 Bi-mAbs and then given human peripheral blood lymphocytes that had been incubated with the CD3-CD30 Bi-mAb and cells that expressed CD30. The enrichment of human T cells within the tumor and the fact that established tumors can be cured may indicate in situ activation of both the T cell receptor and the costimulatory pathway.Keywords
This publication has 30 references indexed in Scilit:
- CD30‐antigen‐specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphomaInternational Journal of Cancer, 1993
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID MiceScience, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992
- Production of tumor necrosis factor-α by naive or memory T lymphocytes activated via CD28Cellular Immunology, 1992
- Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytesCancer Immunology, Immunotherapy, 1991
- Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodiesCancer Immunology, Immunotherapy, 1990
- Immunoscintigraphy of Hodgkin's disease: In vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell linesEuropean Journal of Cancer and Clinical Oncology, 1990
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990